G lycation is the nonenzymatic attachment of a monosaccharide to amino groups of proteins. The reaction has been recognized for many years in the food industry, where it is known as browning (also termed the Maillard reaction) and is responsible for the formation of commonly ingested items, such as toast. In patients with diabetes, glucose accumulation results in enhanced glycation of many proteins, both in tissues (e.g., the lens) and in the blood. Of these, glycated hemoglobin (GHb) is by far the most frequently measured in patient care. Hemoglobin (Hb) in healthy adults consists predominantly of HbA, which has 2a-and 2b-chains. Glucose can attach to several amino acid residues in these chains. HbA 1c is formed when glucose attaches specifically to the NH 2 -terminal valine of the b-chain. Formation of HbA 1c is essentially irreversible, and its concentration in the blood depends on both the life span of the red blood cell (RBC), which averages w120 days, and the blood glucose concentration. Because the rate of formation of HbA 1c is directly proportional to the concentration of glucose in the blood, HbA 1c represents integrated values for glucose over the preceding 8 to 12 weeks (Table 1) .
CLINICAL VALUE OF HbA 1c
Initially described 57 years ago (1), GHb was first reported to be increased in patients with diabetes in the late 1960s (2) . The clinical value of GHb was soon realized and the American Diabetes Association (ADA) began encouraging the routine measurement of GHb in all patients with diabetes (3).
The fundamental role of GHb in diabetes was accentuated by the publication in 1993 of the Diabetes Control and Complications Trial (DCCT) (4). The study, which compared intensive to conventional insulin therapy in patients with type 1 diabetes, documented a direct relationship between blood glucose concentrations (assessed by HbA 1c ) and the risk of microvascular complications. The absolute risks of retinopathy and nephropathy were directly proportional to the mean HbA 1c concentration. (To prevent assay variability [see "Development of Accurate HbA 1c Measurements" below], all GHb assays in the DCCT were performed in a single laboratory that measured HbA 1c ).
Analogous correlations between HbA 1c and complications were observed in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS) (5) . Although mean HbA 1c for intensively treated and conventionally treated type 2 diabetic patients differed by an apparently small amount (values were 7.0 and 7.9%, respectively), microvascular complications in the intensively treated group were w25% lower. Both the DCCT and the UKPDS demonstrated that the HbA 1c value predicts the risk of microvascular complications in patients with diabetes. Importantly, these two large, randomized, prospective studies revealed that the reduction of HbA 1c was associated with a significantly slower progression of microvascular disease (4, 5) . Lowering HbA 1c in subjects with type 1 or type 2 diabetes also significantly reduced myocardial infarction (6,7), a macrovascular complication that is the most common cause of death in people with diabetes.
HbA 1c has many favorable attributes, including no requirement that the patient be fasting, the sample may be collected any time of the day, and the concentration in the blood is independent of acute factors such as stress or exercise (Table 1) (8) . Based on these-and other unique qualities-HbA 1c is firmly established as an index of longterm blood glucose concentrations. In addition, HbA 1c values are used to guide therapy, and target goals have been designated by a number of groups (9) . More recently, HbA 1c has been accepted by several influential diabetes organizations as a criterion for the diagnosis of diabetes (10, 11) .
FACTORS OTHER THAN GLYCEMIA MAY ALTER HbA 1c VALUES
Notwithstanding the ubiquitous use of HbA 1c in diabetes, analogous to any other laboratory test, effective use in patient care requires comprehension of the factors that may influence HbA 1c results (Table 1) . Biological variability. Unlike blood glucose, which fluctuates widely, HbA 1c varies minimally (w1%) in a healthy individual (12) . However, substantial interindividual variation has been observed (13) . Several elements may contribute to this. A concept of variable glycation, with high and low glycators, has been proposed to account for differences observed between HbA 1c and blood glucose values (14) . However, minimal evidence has been published to support the hypothesis, and it remains contentious.
Accumulating data support the concept that race influences HbA 1c , with higher HbA 1c concentrations in African Americans, Asians, and Hispanics than in whites (13) . The etiology is unknown. Some authors posit that the increased HbA 1c accurately reflects higher glucose values in these populations (15) . Regardless of the cause, the differences are small (#0.4% HbA 1c ) and the clinical significance, if any, remains to be established.
Interpretation of HbA 1c depends on RBCs having a normal life span. Patients with hemolytic disease or other conditions with shortened RBC survival exhibit a substantial reduction in HbA 1c (16) . This problem could be resolved if one could correct for the age of RBCs, but unfortunately it is extremely difficult to measure RBC life span.
Factors that may interfere with measurement by some methods. The effects of hemoglobin variants (such as HbS, HbE, HbD, and HbC) are contingent upon the specific method of analysis used (17) . Depending on the particular hemoglobin variant and assay, results may be spuriously increased or decreased. Most manufacturers of HbA 1c assays have modified their methods to eliminate interference from many of the common hemoglobin variants. Therefore, accurate measurement of HbA 1c is possible by selecting an appropriate instrument, provided the RBC life span is not altered (see www.ngsp.org for additional information).
There are isolated reports in the literature of chemical modifications to Hb that affect HbA 1c measurements. Many of these articles are old and use methods that are now obsolete, so their relevance to patient care is not clear. A posttranslational modification of Hb that does interfere with some current methods is carbamylation. The nonenzymatic reaction of isocyanic acid with the NH 2 -terminal valine of Hb (the same residue to which glucose attaches) forms carbamylated Hb. Patients with chronic kidney disease (CKD), a common occurrence in diabetes, have increased carbamylated Hb because of the increased urea, which is in equilibrium with ammonium cyanate. Nevertheless, the majority of the interferents produce relatively small effects, and HbA 1c can be measured accurately in most patients with diabetes. Factors that may affect interpretation. In addition to uremia, patients with CKD have shortened RBC survival and many are on erythropoietin treatment. Together these factors contribute to HbA 1c underestimating glycemic control in patients with CKD (18) . Iron deficiency anemia, by contrast, is associated with higher HbA 1c concentrations (19) . While a population-based study of 10,535 adults in the U.S. observed that iron deficiency was associated with small shifts in HbA 1c values (20) , it seems prudent to correct iron deficiency before measuring HbA 1c .
DEVELOPMENT OF ACCURATE HbA 1c MEASUREMENTS
Tests to measure GHb were launched in 1978 by several companies and the number of methods grew rapidly, with .120 available at the time of writing this article. This created a practical problem as the various methods measured different forms of GHb, resulting in considerably different values for a single patient sample. The situation was compounded by the complete absence of standardization, producing as much as a twofold difference in GHb values (e.g., 4.0 and 8.1%) in a sample analyzed by two different methods (9) . This variability, which was not well recognized by most clinicians, substantially limited the value of GHb measurement in patient care.
The necessity for accurate HbA 1c measurement motivated the formation of the NGSP, which standardizes HbA 1c results to those of the DCCT. This function is performed by a network of laboratories that are centered around the Primary Reference Laboratory, which uses the HbA 1c method used in the DCCT (21) . The NGSP laboratory network collaborates with manufacturers of HbA 1c assays so that their instruments will report the same HbA 1c value as that reported in the DCCT (21) . In other words, an HbA 1c of 8.0% in a patient sample should be identical to a value of 8.0% in the DCCT. Using mass spectrometry, a working group of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) developed a reference method to accurately quantify HbA 1c (22, 23) . This reference measurement procedure is not intended for routine analysis of patient samples, but has traceability to a standard of higher metrologic order. The complementary efforts of the NGSP and the IFCC have led to significant improvements in the accuracy of HbA 1c measurement in routine patient testing (21) .
HOW IS HbA 1c REPORTED?
HbA 1c has traditionally been reported as a percentage of total Hb. IFCC numbers are lower by 1.5-2.0% HbA 1c than NGSP/DCCT numbers, most likely because of the increased specificity of the IFCC method. While there is a tight linear correlation between the NGSP and the IFCC methods, the slope and intercept differ significantly from 1 and 0, respectively (23 (25) . A test for glycated albumin alone has also been developed (26) . These extracellular analytes reflect glycemia over w10-14 days (the half-life of albumin) and are independent of both RBC life span and Hb modifications. However, they are altered by changes in albumin turnover and suffer from a dearth of clinical studies. A PubMed search in humans resulted in 23,210 "hits" for HbA 1c , but only 1,526 and 478 for fructosamine and glycated albumin, respectively. More importantly, there are neither outcome data that unequivocally link these analytes to diabetes complications nor agreed target values for optimum glycemic control. While they have a role in situations where HbA 1c cannot be used, their clinical value is limited until more data become available.
It is important to emphasize that the measurement of HbA 1c provides valuable information for the overwhelming majority of diabetic patients. Knowledge of the conditions that alter HbA 1c enables the appropriate use of HbA 1c , which will remain, for the foreseeable future, essential for the management of patients with diabetes.
